and timing. Any forward-looking statements are based on management's current 
  views and assumptions and involve risks and uncertainties that could cause 
       actual results, performance or events to differ materially from those 
      expressed or implied in such statements. These risks and uncertainties 
     include, but are not limited to, the risks that Autolus' preclinical or 
 clinical programs do not advance or result in approved products on a timely 
 or cost effective basis or at all; the results of early clinical trials are 
 not always being predictive of future results; the cost, timing and results 
     of clinical trials; that many product candidates do not become approved 
  drugs on a timely or cost effective basis or at all; the ability to enroll 
 patients in clinical trials; possible safety and efficacy concerns; and the 
         impact of the ongoing COVID-19 pandemic on Autolus' business. For a 
   discussion of other risks and uncertainties, and other important factors, 
       any of which could cause Autolus' actual results to differ from those 
   contained in the forward-looking statements, see the section titled "Risk 
   Factors" in Autolus' Annual Report on Form 20-F filed with the Securities 
and Exchange Commission on March 3, 2020, as amended, as well as discussions 
  of potential risks, uncertainties, and other important factors in Autolus' 
         subsequent filings with the Securities and Exchange Commission. All 
 information in this press release is as of the date of the release, and the 
     company undertakes no obligation to publicly update any forward-looking 
        statement, whether as a result of new information, future events, or 
                                       otherwise, except as required by law. 
 
                                                                    Contact: 
 
                                                       Lucinda Crabtree, PhD 
 
             Vice President, Investor Relations and Corporate Communications 
 
                                                        +44 (0) 7587 372 619 
 
                                                      l.crabtree@autolus.com 
 
                                                                Julia Wilson 
 
                                                         +44 (0) 7818 430877 
 
                                                        j.wilson@autolus.com 
 
                                                             Susan A. Noonan 
 
                                                  S.A. Noonan Communications 
 
                                                             +1-212-966-3650 
 
                                                          susan@sanoonan.com 
 
ISIN:           GB00BD045071 
Category Code:  MSCU 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be 
                disclosed under the laws of a Member State 
Sequence No.:   89203 
EQS News ID:    1153415 
 
End of Announcement EQS News Service 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=c04c741750d4a6a71d38d0f56e8eb2c7&application_id=1153415&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1153415&site_id=vwd&application_name=news 
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=692e09671580f15b5c593071330f93ca&application_id=1153415&site_id=vwd&application_name=news 
4: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=080248b0abbd12b28e9c158d07849135&application_id=1153415&site_id=vwd&application_name=news

(END) Dow Jones Newswires

December 07, 2020 12:47 ET (17:47 GMT)